IP Library Patent Application 17558919
Patent Application
App. No. 17/558,919

Non-Aqueous Liquid Nimodipine Compositions

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/558,919
Abstract

Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.

Claims (12)

1 .- 20 . (canceled)

21 . A composition comprising nimodipine and polyethylene glycol, wherein about 5% or less nimodipine degradation is observed over a period of at least three months when exposed to 40° C. and 75% relative humidity and the concentration of nimodipine is greater than about 3 mg/mL.

22 . The composition of claim 21 , wherein the concentration of nimodipine is about 6 mg/mL.

23 . The composition of claim 21 , wherein the composition further comprises ethanol and/or glycerin.

24 . The composition of claim 21 , further comprising from about 0.01% to about 1.5% nimodipine related compound A.

25 . The composition of claim 21 , wherein the concentration of nimodipine is greater than about 6 mg/mL.

26 . The composition of claim 21 , wherein nimodipine is present in an amount from about 10 mg to about 100 mg per dosage unit.

27 . The composition of claim 21 , wherein nimodipine is present in an amount of about 60 mg per dosage unit.

28 . A method of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms comprising administering to a patient in need thereof an effective amount of the composition of claim 21 .

29 . The method of claim 28 , wherein the composition is administered orally, via nasogastric tube or via gastric tube.

30 . The method of claim 28 , wherein a first unit dose of the composition is administered to the patient within about 100 hours of the subarachnoid hemorrhage.

31 . The method of claim 28 , wherein the composition is administered about every four hours.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2024
From: ARBOR PHARMACEUTICALS, LLC
To: AZURITY PHARMACEUTICALS, INC.
Reel/Frame 066612/0541 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 29, 2024
From: ARBOR PHARMACEUTICALS, LLC
To: AZURITY PHARMACEUTICALS, INC.
Reel/Frame 066606/0379 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2022
From: ARBOR PHARMACEUTICALS, LLC
To: AZURITY PHARMACEUTICALS, INC.
Reel/Frame 060291/0254 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2021
From: THOMAS, HUGH GREG
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 058479/0928 →